Apomorphine still looks faster than ropinirole for canine emesis

The clinical debate over apomorphine versus ropinirole is getting more specific, and more useful, for veterinary teams. VetGirl’s podcast on the topic lands as new comparative data suggest the answer isn’t simply whether both drugs can induce vomiting in dogs, but how they perform under real emergency conditions. Ropinirole ophthalmic solution, sold as Clevor, has the regulatory advantage as the first FDA-approved emetic for dogs in the U.S., but newer evidence indicates IV apomorphine may still have the edge when speed is the priority. (fda.gov)

That context matters because apomorphine has long been widely used in practice despite lacking FDA approval for this indication in the United States. University of Illinois’ veterinary pharmacy guidance notes that apomorphine is used extra-label for emesis induction in dogs, while Clevor is the labeled ophthalmic option for dogs at least 4.5 months old and at least 1.8 kg. In other words, the market has shifted from a single common off-label choice to a two-option decision with different regulatory and operational tradeoffs. (vetmed.illinois.edu)

The strongest recent comparison comes from a 2025 Veterinary Emergency and Critical Care study summarized in PubMed. In dogs presenting to an emergency department for decontamination, ropinirole had an 81% first-dose success rate versus 99% for apomorphine, a median time to first emetic event of 8.6 minutes versus 1.6 minutes, and required antiemetic rescue in 37% of cases compared with 0% for apomorphine. The authors concluded that apomorphine was clinically superior in that emergency setting because it produced faster, more reliable emesis with less protracted vomiting. (pubmed.ncbi.nlm.nih.gov)

A second 2025 study, published in Frontiers in Veterinary Science, offered a more favorable read on ropinirole, at least in healthy dogs under controlled conditions. In that blinded randomized crossover trial, both drugs were highly effective overall, with emesis success rates of 95.8% for apomorphine and 100% for ropinirole. But the study still found a significantly shorter median time to onset with apomorphine, 1.18 minutes versus 8.85 minutes, and noted more ocular redness and episodes of protracted vomiting in the ropinirole group. Taken together, the two studies suggest that ropinirole can work well, but its performance may be more context-dependent than the FDA label alone would imply. That’s an inference based on the contrast between healthy-dog trial data and emergency-department data. (pmc.ncbi.nlm.nih.gov)

Product positioning also shapes the discussion. Vetoquinol markets Clevor as a ready-to-use, single-use ophthalmic product for in-clinic administration by veterinary professionals, with label warnings against use in dogs with seizures, CNS depression, ingestion of corrosives or sharp foreign objects, or ocular injury. Those features may make it attractive for clinics that value a needle-free labeled option, particularly when IV access is not already in place. ASPCApro similarly notes that ropinirole is a newer emetic with more limited publications, while apomorphine remains a well-established option in dogs because of dopamine-mediated emesis. (vetoquinolusa.com)

Why it matters: For veterinary professionals, this is really a protocol question. If the patient is in an emergency setting and rapid decontamination is essential, the current comparative evidence supports IV apomorphine as the more dependable choice. If a clinic prioritizes labeled use, simpler administration, or avoiding injections, ropinirole may still be a reasonable option, as long as teams are prepared for slower onset and a higher chance of prolonged vomiting or antiemetic rescue. That affects staffing, discharge instructions, inventory decisions, and how clinicians counsel pet parents about what to expect after emesis induction. (pubmed.ncbi.nlm.nih.gov)

There’s also a broader pharmacology backdrop here. While your second source concerns antiemesis rather than emesis induction, Dechra’s FDA-approved Emeprev, a bioequivalent injectable maropitant product approved in December 2025 and expected to be available through major distributors in early 2026, underscores how much attention companies are paying to vomiting management workflows. Beyond simple availability, Emeprev is being positioned around practical clinic advantages: it contains benzyl alcohol, which Dechra says reduces injection pain in dogs by acting as a local anesthetic, and it does not require refrigeration, which may simplify storage and access in busy practices. The product is indicated for prevention and treatment of acute vomiting in dogs and for treatment of vomiting in cats, with SC or IV use in adults and SC use in puppies 2 to 4 months old. In other words, even though it is not an emetic, it fits directly into the same case pathway when a dog needs rescue antiemetic support after induced vomiting. (dechra-us.com)

What to watch: The next step is more real-world comparison data, especially in poisoned dogs, foreign-body cases, and general practice settings where route of administration and staff workflow can matter as much as raw efficacy. If those data continue to show a gap between controlled-trial performance and emergency-use performance, clinics may end up reserving ropinirole for selected cases while keeping apomorphine as the go-to for time-sensitive decontamination. It’s also worth watching whether newer antiemetic options such as Emeprev change rescue-treatment preferences by offering the same maropitant effect with easier storage and potentially less painful injections. (pubmed.ncbi.nlm.nih.gov)